...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker
【24h】

Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker

机译:通过基于聚乙二醇的可裂解接头增强阿霉素-单克隆抗体偶联物的肿瘤细胞选择性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A novel linker consisting of poly(ethylene glycol) (PEG) and dipeptide was used for conjugation of adriamycin with tumor-specific monoclonal antibody, NL-1, to confirm that the linker can be cleaved selectively with the tumor specific enzyme to express cytotoxicity of the anti-tumor agent. Initially, adriamycin-conjugated PEG linkers through different amino acid compositions. alanyl-valine (Ala-Val), alanyl-proline (Ala-Pro), and glycyl-proline (Gly-Pro) sequences, were prepared to confirm selective digestion with model enzymes. Adriamycin was released by particular model endoproteases, thermolysin and proline endopeptidase, from the linkers with different efficiency. When conjugates were prepared using these adriamycin-bound linkers. conjugates had no loss of binding affinity and speciftcity for common acute lymphoblastic leukemia antigen (CALLA) expressed on the Saudi cell surfaces as the target of NL-1 antibody. In addition, adriamycin release from the conjugates was also confirmed by incubating them with specific proteases. Tumor cell growth was inhibited dose-dependently for the conjugates carrying Ala-Val and Gly-Pro linkers, whereas significant inhibitory effect was abolished for the conjugate carrying Ala-Pro linker, indicating that cytotoxic effect can be controlled by specificity of antibody and composition of linker peptide. IC50 for Ala-Val linked conjugate was approximately 3.5 mug/ml and that for Gly-Pro linked conjugate was 5.2 mug/ml. PEG-dipeptidyl linker demonstrated here will be an effective tool for the preparation of immunoconjugate. especially specific activation of anti-tumor agents at desired tumor tissues. (C) 2002 Elsevier Science B.V. All rights reserved. [References: 36]
机译:使用由聚乙二醇(PEG)和二肽组成的新型连接子将阿霉素与肿瘤特异性单克隆抗体NL-1偶联,以确认该连接子可以被肿瘤特异性酶选择性裂解,从而表达阿霉素的细胞毒性。抗肿瘤剂。最初,阿霉素缀合的PEG连接子通过不同的氨基酸组成。制备了丙氨酰-缬氨酸(Ala-Val),丙氨酰-脯氨酸(Ala-Pro)和甘氨酰-脯氨酸(Gly-Pro)序列,以确认用模型酶的选择性消化。阿霉素由特定模型的内切蛋白酶,嗜热菌蛋白酶和脯氨酸内肽酶以不同的效率从接头释放。当使用这些结合阿霉素的接头制备缀合物时。结合物对作为NL-1抗体靶标的沙特细胞表面表达的常见急性淋巴细胞白血病抗原(CALLA)的结合亲和力和特异性没有损失。另外,还通过与特异性蛋白酶一起孵育来证实阿霉素从结合物中释放。带有Ala-Val和Gly-Pro接头的结合物对肿瘤细胞的生长具有剂量依赖性,而带有Ala-Pro接头的结合物的肿瘤抑制作用被取消,这表明细胞毒性作用可以通过抗体的特异性和其组成来控制。接头肽。 Ala-Val连接缀合物的IC50约为3.5杯/毫升,而Gly-Pro连接缀合物的IC50则为5.2杯/毫升。本文展示的PEG-二肽基接头将是制备免疫偶联物的有效工具。特别是在所需肿瘤组织上抗肿瘤剂的特异性活化。 (C)2002 Elsevier Science B.V.保留所有权利。 [参考:36]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号